STAAR Surgical posts strong Q3 2026 results and launches $50 M share buyback
STAAR Surgical reported third‑quarter 2026 revenue of $83.4 million, well above analysts’ $78.74 million estimate, and adjusted earnings of $0.28 per share, far beating the $0.05 consensus. Adjusted EBITDA reached $14.4 million and cash reserves stood at $206.4 million. The company announced a $50 million share repurchase program and highlighted 31% revenue growth excluding prior‑year adjustments, driven by strong demand for its EVO+ lenses in China.
Why it matters
Stifel raised its price target on STAAR Surgical to $34 from $31, citing the robust China demand and the earnings beat. The newly authorized $50 million buyback signals management’s confidence in the business and could support the stock price.
Key facts
- 1Q3 2026 revenue was $83.4 million, beating the $78.74 million estimate. investing.com
- 2Adjusted earnings per share were $0.28, exceeding the $0.05 expected. investing.com
- 3Adjusted EBITDA was $14.4 million. finance.yahoo.com
- 4Cash reserves totaled $206.4 million. finance.yahoo.com
- 5The board authorized a $50 million share repurchase program. seekingalpha.com
- 6Revenue grew 31% excluding prior‑year adjustments. finance.yahoo.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.